Aberdeen Royal Infirmary Launches CAR-T Cell Therapy Program, First Patient Achieves Remission
Key Insights
Aberdeen Royal Infirmary has been designated as the regional CAR-T treatment center for northern Scotland, eliminating the need for patients to travel hundreds of miles to Newcastle for this life-saving therapy.
Nancy Gray, 68, became the first patient to receive CAR-T therapy (search) at the facility in November 2024 and achieved remission by July, demonstrating the treatment's effectiveness for relapsed lymphoma (search).
The revolutionary cellular immunotherapy reprograms patients' own T-cells (search) to recognize and destroy cancer (search) cells, offering hope for blood cancer patients who haven't responded to conventional treatments like chemotherapy (search).
Aberdeen Royal Infirmary has achieved a significant milestone in cancer (search) care by becoming the regional CAR-T (Chimeric Antigen Receptor T Cell) treatment center for northern Scotland, with the first patient to receive this groundbreaking therapy now in complete remission.
Nancy Gray, a 68-year-old from Aberdeen, made medical history as the first patient to undergo CAR-T therapy (search) at the facility in November 2024. Following a scan in July, doctors confirmed she had achieved remission from lymphoma (search) that had failed to respond to conventional chemotherapy (search).
"I'm absolutely over the moon," Gray said. "There were a lot of tears that day. I'm lucky I got it done here – some people haven't been that lucky."
Revolutionary Treatment Mechanism
CAR-T therapy (search) represents a paradigm shift in cancer (search) treatment, utilizing the patient's own immune system to fight malignancy. The procedure involves collecting T-cells (search) – white blood cells that protect against disease – from the patient and genetically modifying them in a laboratory to recognize and destroy cancer cells. These reprogrammed cells are then infused back into the patient to mount a targeted attack against the cancer.
Consultant haematologist Gavin Preston described the treatment as "a massive breakthrough" and "a new way of treating cancer (search) which uses a specific cellular mechanism, different from standard chemotherapy (search)."
The therapy is specifically indicated for patients with blood cancers, including lymphoma (search) and leukemia (search), who have experienced relapse and haven't responded to other treatments such as chemotherapy (search) or transplants.
Addressing Geographic Healthcare Disparities
The establishment of Aberdeen Royal Infirmary as a regional CAR-T center addresses a critical gap in healthcare access for patients across northern Scotland. Previously, patients requiring this treatment faced arduous journeys to Newcastle, involving 500-mile round trips.
"Previously, patients had to travel to Newcastle. I've personally treated someone who wouldn't even travel to Glasgow – he's only still with us because we were able to give this treatment here," Preston explained. "It's a huge benefit to patients across the north, north-east and the islands to have access closer to home."
Richard Jennings, 62, from Aberdeen, exemplifies the challenges patients faced before the local program launched. He underwent CAR-T therapy (search) in Newcastle for Non-Hodgkin's lymphoma (search) that didn't respond to chemotherapy (search).
"Going to Newcastle was obviously more effort than being here in the north-east, but it gave me a chance to live, which was fantastic," Jennings said. "There's no doubt it's great it's available in Aberdeen now – I was just slightly too early. Some people are less able to travel than I was."
Patient Journey and Clinical Impact
Gray's medical journey illustrates both the challenges of cancer (search) recurrence and the promise of advanced cellular therapies. Initially diagnosed with cancer in her spleen in 2023, she received the all-clear in April 2024. However, within weeks, the disease returned as a lymphoma (search) mass behind her nose, discovered during a holiday in Blackpool when she experienced severe sinus pain.
"I was devastated. It's the one thing you don't think of – it's unthinkable, unbelievable what goes through your mind," Gray recalled. "I thought, I've beaten it once, I'll beat it again."
When conventional chemotherapy (search) failed, CAR-T therapy (search) offered a lifeline. The treatment process, while initially frightening for Gray, proved successful. Clinical nurse specialist Laura Mallarkey described the treatment as "life-changing" for patients and their families.
Institutional Excellence and Future Implications
The designation of Aberdeen Royal Infirmary as a CAR-T center represents more than expanded treatment access – it establishes the facility as a center of excellence in hematology. Preston noted that this status "will attract high quality staff to work in the region as well as improving training and education for our teams."
The program benefits from comprehensive support services, including partnerships with third-sector organizations such as Haven, Maggies, and Friends of Anchor, which provide crucial support for patients and families throughout the treatment journey.
Gray's successful outcome demonstrates the potential of CAR-T therapy (search) to transform outcomes for patients with refractory blood cancers. Her husband Jim described the emotional impact of her remission: "I burst out crying. Nancy's gone through everything, but for me it felt like somebody had just taken an anvil off my chest. I could breathe again."